サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427749

慢性骨髄性白血病（CML）治療の世界市場レポート2024

Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
慢性骨髄性白血病（CML）治療の世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

慢性骨髄性白血病（CML）治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.2%の年間複合成長率（CAGR）で104億米ドルに成長すると予想されます。予測期間で予想される成長は、個別化医療アプローチの採用、併用療法の開発、新しい治療法への患者アクセスの改善、希少疾病用医薬品を支援する政府の政策、および全体的なヘルスケア費の増加に起因すると考えられます。予測期間の主な動向には、調査活動における世界の協力、遠隔医療と遠隔モニタリングの普及、次世代チロシンキナーゼ阻害剤（TKI）の進歩、治療最適化戦略の実施などが含まれます。これらの動向は集合的に、慢性骨髄性白血病（CML）治療の情勢に貢献しています。

慢性骨髄性白血病（CML）の発生率と有病率の予想される増加は、慢性骨髄性白血病（CML）治療市場の成長の重要な推進力になると予想されます。慢性骨髄性白血病としても知られるこのタイプの白血病は、未熟な骨髄細胞の過剰な産生を引き起こすことで骨髄と血液に重大な影響を与えます。慢性骨髄性白血病の治療は、その進行を遅らせ、より重篤な段階への進行を防ぐために非常に重要です。たとえば、2023年 3月の米国臨床腫瘍学会のデータに基づくと、米国では約35,730人というかなりの数の人が多発性骨髄腫と診断されると予想されています。さらに、2023年にはこの病気により約12,590人が死亡すると予想されています。これらの統計は、効果的な治療法の差し迫った必要性を強調しており、それによって慢性骨髄性白血病（CML）治療市場の成長を推進しています。

個別化医療の出現は、慢性骨髄性白血病（CML）治療市場の拡大に大きく貢献しました。個別化医療には、患者の遺伝子構造の包括的な理解に基づいて、患者に合わせた治療計画と意思決定プロセスが含まれます。 CMLに関しては、このアプローチにより特定の分子標的、特にBCR-ABL融合遺伝子の同定が可能になり、個々の患者の疾患を引き起こす遺伝子異常を正確に理解できるようになります。この理解により、早期介入と個別の予防措置の実施への道が開かれます。たとえば、スウェーデン政府によるゲノム医療スウェーデン（GMS）国家インフラへの2億2,000万スウェーデンクローナ（2,115万米ドル）の投資は、精密医療を国のヘルスケアシステムに統合することを目的としています。さらに、個別化医療連合（PMC）が強調しているように、個別化医療に対する需要の高まりは、2022年に米国食品医薬品局による新薬承認の34%をこれらの薬剤が占める可能性があることを示しており、慢性骨髄性白血病（CML）治療の市場成長の予測をさらに裏付けています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の慢性骨髄性白血病（CML）治療市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 標的療法
  • 化学療法
  • 放射線治療
  • 脾臓摘出術
  • 幹細胞移植
  • 世界の慢性骨髄性白血病（CML）治療市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • チロシンキナーゼ阻害剤
  • 代謝拮抗物質
  • その他
  • 世界の慢性骨髄性白血病（CML）治療市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 診療所
  • その他
  • 世界の慢性骨髄性白血病（CML）治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界の慢性骨髄性白血病（CML）治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の慢性骨髄性白血病（CML）治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 慢性骨髄性白血病（CML）治療市場の競合情勢
  • 慢性骨髄性白血病（CML）治療市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Bayer AG

第31章 その他の大手および革新的な企業

  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eisai Co. Ltd.
  • Fresenius Kabi AG
  • Sun Pharmaceutical Industries Ltd.
  • Hospira Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Incyte Corporation
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13593

Chronic myeloid leukemia (CML) treatment involves addressing the uncontrolled growth of abnormal white blood cells in the blood and bone marrow. These cells, known as myeloid cells, play a crucial role in fighting infections and maintaining the immune system.

The primary types of CML treatment include targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplant. Targeted therapy is a cancer treatment approach that employs drugs to specifically target genes and proteins supporting the growth and survival of cancer cells. In the context of CML treatment, targeted therapy aims to identify and eliminate specific cancer cell types while minimizing damage to healthy cells. Various drugs, including tyrosine kinase inhibitors, antimetabolites, and others, are utilized in hospitals, clinics, and other healthcare settings for CML treatment. These medications are accessible through hospital pharmacies, retail pharmacies, and online pharmacy platforms.

The chronic myeloid leukemia (CML) treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia (CML) treatment market statistics, including the chronic myeloid leukemia (CML) treatment industry's global market size, regional shares, competitors with a chronic myeloid leukemia (CML) treatment market share, detailed chronic myeloid leukemia (CML) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic myeloid leukemia (CML) treatment industry. This chronic myeloid leukemia (CML) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic myeloid leukemia (cml) treatment market size has grown strongly in recent years. It will grow from $7.73 billion in 2023 to $8.18 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be attributed to several factors, including heightened awareness and early detection practices, positive outcomes from clinical trials, advancements in the development of targeted therapies, the presence of patient advocacy and support groups, and the ongoing development of healthcare infrastructure. These elements collectively contributed to the progress and improvement in the landscape of chronic myeloid leukemia (CML) treatment during the historic period.

The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $10.4 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to the adoption of personalized medicine approaches, the development of combination therapies, improved patient access to novel treatments, government policies supporting orphan drugs, and the overall increase in healthcare expenditure. Key trends in the forecast period include global collaboration in research efforts, the widespread adoption of telemedicine and remote monitoring, advancements in next-generation tyrosine kinase inhibitors (TKIs), and the implementation of treatment optimization strategies. These trends collectively contribute to the evolving landscape of chronic myeloid leukemia (CML) treatment.

The projected rise in the incidence and prevalence of chronic myeloid leukemia (CML) is anticipated to be a significant driver of growth in the chronic myeloid leukemia (CML) treatment market. This type of leukemia, also known as chronic myelogenous leukemia, profoundly impacts the bone marrow and blood by causing an excessive production of immature myeloid cells. Treatment for chronic myeloid leukemia is crucial in slowing down its progression and preventing its advancement to more severe stages. For instance, based on data from the American Society of Clinical Oncology in March 2023, the United States expects a substantial number of individuals, around 35,730, to be diagnosed with multiple myeloma. Furthermore, approximately 12,590 deaths due to this disease are anticipated in 2023. These statistics underscore the pressing need for effective treatments, thereby driving the growth of the chronic myeloid leukemia (CML) treatment market.

The advent of personalized medicine has significantly contributed to the expansion of the chronic myeloid leukemia (CML) treatment market. Personalized medicine involves tailoring treatment plans and decision-making processes for patients based on a comprehensive understanding of their genetic makeup. In the context of CML, this approach enables the identification of specific molecular targets, notably the BCR-ABL fusion gene, allowing for a precise comprehension of the genetic irregularities driving the disease in individual patients. This understanding paves the way for early interventions and the implementation of personalized preventive measures. For example, the Swedish Government's investment of SEK 220 million ($21.15 million) in the Genomic Medicine Sweden (GMS) national infrastructure is aimed at integrating precision medicine into the country's healthcare system. Additionally, the rising demand for personalized medicines, as highlighted by the Personalized Medicine Coalition (PMC), indicates that these medicines could constitute 34% of new drug approvals by the US Food and Drug Administration in 2022, further supporting the anticipated growth of the chronic myeloid leukemia (CML) treatment market.

Product innovation stands as a pivotal trend shaping the landscape of the chronic myeloid leukemia (CML) treatment market. Companies engaged in this sector are actively embracing novel technologies to fortify their market presence. For instance, Novartis, a Switzerland-based pharmaceutical giant, achieved FDA approval for Scemblix (asciminib) in October 2021, marking a significant milestone as the first FDA-approved treatment for chronic myeloid leukemia. Scemblix operates by binding to the ABL myristoyl pocket, catering to patients facing resistance or intolerance to existing TKI therapies. Impressively, Scemblix demonstrated superior performance compared to Bosulif (bosutinib) over 24 weeks, boasting a higher major molecular response (MMR) rate at 25% versus 13% and significantly lower discontinuation rates due to adverse effects at 7% versus 25%.

Strategic partnerships and collaborations are key focal points for companies aiming to broaden their product spectrum and geographical footprint. For instance, Xspray Pharma, a Sweden-based biotechnology company, forged a partnership with EVERSANA, a US-based life sciences entity, in February 2023. This collaboration aims to support the US launch and commercialization of Dasynoc (XS004), a promising treatment for chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Though pending FDA approval and contingent upon legal conditions, Dasynoc signifies a novel treatment option anticipated to penetrate the lucrative $3.5 billion Tyrosine Kinase Inhibitors market in the United States. Leveraging EVERSANA's specialized commercialization team entrenched in the oncology market, Xspray aims for a tailored and effective approach to introduce Dasynoc, with a projected launch slated for the latter half of 2023. This strategic move holds the promise of significantly enhancing treatment options for CML and ALL patients within the US market.

In August 2022, the US-based multinational pharmaceutical company Bristol Myers Squibb successfully acquired Turning Point Therapeutics for $4.1 billion. This strategic acquisition provides Bristol Myers Squibb with access to Turning Point Therapeutics' pipeline of experimental drugs, notably repotrectinib, designed to target prevalent mutations associated with oncogenesis. Turning Point Therapeutics, based in the US, specializes in the development of precision medicines for cancer and other diseases, including tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia (CML).

Major companies operating in the chronic myeloid leukemia (cml) treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hospira Inc., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Stragen Pharma SA, Orca Bio, Bio-Path Holdings Inc.

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2023. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic myeloid leukemia (cml) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia (CML) treatment market includes revenues earned by entities by providing targeted therapy with tyrosine kinase inhibitors (TKIs). The chronic myeloid leukemia market includes Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Asciminib. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia (cml) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic myeloid leukemia (cml) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic myeloid leukemia (cml) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
  • 2) By Drug Type: Tyrosine Kinase Inhibitors; Antimetabolites; Other Drug Types
  • 3) By Application: Hospitals; Clinic; Other Applications
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Myeloid Leukemia (CML) Treatment Market Characteristics

3. Chronic Myeloid Leukemia (CML) Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia (CML) Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Chronic Myeloid Leukemia (CML) Treatment Market Size and Growth

  • 5.1. Global Chronic Myeloid Leukemia (CML) Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Chronic Myeloid Leukemia (CML) Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Chronic Myeloid Leukemia (CML) Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chronic Myeloid Leukemia (CML) Treatment Market Segmentation

  • 6.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Splenectomy
  • Stem Cell Transplant
  • 6.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tyrosine Kinase Inhibitors
  • Antimetabolites
  • Other Drug Types
  • 6.3. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinic
  • Other Applications
  • 6.4. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Chronic Myeloid Leukemia (CML) Treatment Market Regional And Country Analysis

  • 7.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market

  • 8.1. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chronic Myeloid Leukemia (CML) Treatment Market

  • 9.1. China Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 9.2. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chronic Myeloid Leukemia (CML) Treatment Market

  • 10.1. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chronic Myeloid Leukemia (CML) Treatment Market

  • 11.1. Japan Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 11.2. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chronic Myeloid Leukemia (CML) Treatment Market

  • 12.1. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market

  • 13.1. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chronic Myeloid Leukemia (CML) Treatment Market

  • 14.1. South Korea Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 14.2. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market

  • 15.1. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 15.2. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chronic Myeloid Leukemia (CML) Treatment Market

  • 16.1. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chronic Myeloid Leukemia (CML) Treatment Market

  • 17.1. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chronic Myeloid Leukemia (CML) Treatment Market

  • 18.1. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chronic Myeloid Leukemia (CML) Treatment Market

  • 19.1. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chronic Myeloid Leukemia (CML) Treatment Market

  • 20.1. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market

  • 21.1. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 21.2. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chronic Myeloid Leukemia (CML) Treatment Market

  • 22.1. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chronic Myeloid Leukemia (CML) Treatment Market

  • 23.1. North America Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 23.2. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chronic Myeloid Leukemia (CML) Treatment Market

  • 24.1. USA Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 24.2. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chronic Myeloid Leukemia (CML) Treatment Market

  • 25.1. Canada Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 25.2. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chronic Myeloid Leukemia (CML) Treatment Market

  • 26.1. South America Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 26.2. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chronic Myeloid Leukemia (CML) Treatment Market

  • 27.1. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chronic Myeloid Leukemia (CML) Treatment Market

  • 28.1. Middle East Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 28.2. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chronic Myeloid Leukemia (CML) Treatment Market

  • 29.1. Africa Chronic Myeloid Leukemia (CML) Treatment Market Overview
  • 29.2. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape
  • 30.2. Chronic Myeloid Leukemia (CML) Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Chronic Myeloid Leukemia (CML) Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca plc
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Amgen Inc.
  • 31.6. Viatris Inc.
  • 31.7. Teva Pharmaceutical Industries Ltd.
  • 31.8. Eisai Co. Ltd.
  • 31.9. Fresenius Kabi AG
  • 31.10. Sun Pharmaceutical Industries Ltd.
  • 31.11. Hospira Inc.
  • 31.12. Otsuka Pharmaceutical Co. Ltd.
  • 31.13. Incyte Corporation
  • 31.14. Cipla Limited
  • 31.15. Dr. Reddy's Laboratories Ltd.

32. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Benchmarking

33. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia (CML) Treatment Market

35. Chronic Myeloid Leukemia (CML) Treatment Market Future Outlook and Potential Analysis

  • 35.1 Chronic Myeloid Leukemia (CML) Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Chronic Myeloid Leukemia (CML) Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Chronic Myeloid Leukemia (CML) Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer